That is their primary therapeutic effect for weight management
This approach common to GLP-1 and related receptor agonist therapies is designed to minimise gastrointestinal side effects such as nausea, vomiting, and diarrhoea, which are among the most frequently reported adverse events with this class of medication
Specifically: North Dakota updated its essential health benefit (EHB) benchmark plan under the Affordable Care Act to require, beginning in 2025 , prescription drug coverage of GLP-1s and GIPs as therapy for prevention of diabetes and treatment of insulin resistance, metabolic syndrome or morbid obesity
Not for human consumption, clinical use, or veterinary application.
Since the start of 2025, OZEM is up 28.62%, sharply outpacing the S&P 500 Health Care Sector (8.55%) and the broader S&P 500 Index (12.76%)
In fact, a 2024 study revealed that only 20% of patients managed to keep their weight loss within 25% of their goal after stopping semaglutide for a year
